Carregant...
Clinical considerations for the development of biosimilars in oncology
Despite availability of biologic therapies, limited patient access to many of the most-effective cancer treatments affects overall health outcomes. To address this issue, many governments have enacted legislation for the approval of biosimilars. The term “biosimilar” refers to a biologic product tha...
Guardat en:
| Publicat a: | MAbs |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4623533/ https://ncbi.nlm.nih.gov/pubmed/25621390 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2015.1008346 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|